The Indian Journal of Pediatrics

, Volume 71, Issue 8, pp 721–727 | Cite as

Newer drugs for asthma

Symposium on Pulmonology


Several new drugs have resulted from innovative pharmacological and immunomodulatory approaches towards treatment of asthma. Diverse therapeutic targets have provided new agents. The new classes of drugs available are newer “on site activated inhaled corticisteroids” and soft steroids, anti IgE compounds, leukotriene inhibitors and single isomer agents which are available for clinical use. Anti interleukin agents and phosphodiesterase inhibitors are in the stage of clinical trials. Antisense therapy and pharmacogenetics are the on horizon for treatment of asthma.


Inhaled corticosteroids IgE Interleukins 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    National Heart Lung and Bloood Institute, Expert Panel Report Guidelines for the diagnosis and management of asthma. National Institutes of Health, Bathesda HD, 1997 Publication No. 95-3659.Google Scholar
  2. 2.
    Dahl R, Nielson LP, Christensen MB, Engelstatter R. Ciclesonide-an inhaled corticosteroid prodrug inhibits allergen induced early and late phase reactions.Eur Respir J 1998; 28: 62.Google Scholar
  3. 3.
    Bodor N, Buchwald P. Soft drug design. General principles and recent applications.Med Res Rev 2000; 20: 58–101.PubMedCrossRefGoogle Scholar
  4. 4.
    Bennich HH, Ishizaka K, Johansson SGOel al. Immunoglobulin E, a new class of human immunoglobulin.Bull WHO 1968; 38: 151–152.Google Scholar
  5. 5.
    Burrows B, Martinez FD, Halonen Met al. Association of asthma with serum IgE levels and skin-test reactivity to allergens.N Engl J Med 1989; 320: 271–277.PubMedCrossRefGoogle Scholar
  6. 6.
    Sears MR, Burrows B, Flannery EMet al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children.N Engl J Med 1991; 325: 1067–1071.PubMedCrossRefGoogle Scholar
  7. 7.
    Milgrom H, Fick RB, Su JQet al. Treatment of allergic asthma with monoclonal anti-IgE antibody.N Engl J Med 1999; 341: 1966–1973.PubMedCrossRefGoogle Scholar
  8. 8.
    Benson M, Strannegard II, Wennergren G, Strannegard O. Cytokines in nasal fluids from school children with seasonal allergic rhinitis.Pedktric Allergy Immunol 1997; 8: 143–149.CrossRefGoogle Scholar
  9. 9.
    Borish L, Nelson H, Lanz M, Claussen L, Whitmore J, Agosti Jet al. Recombinant human interleukin-4 receptor in moderate astopic asthma: A randomized double-blind, placebocontrolled pilot study.Am J Respir Crit Care Med 1999; 160: 1816–1823.PubMedGoogle Scholar
  10. 10.
    Leckie MJ, ten Brinke A, Lordan J, Khan J, Diamant Z, Walls CMet al. SB 240563, a humanised anti-IL-5 monoclonal antibody: initial single dose safety and activity in patients with asthma.Am J Respir Crit Care Med 1999; 159: A624.Google Scholar
  11. 11.
    Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo.J Exp Med 1995; 182: 1169–1174.PubMedCrossRefGoogle Scholar
  12. 12.
    Torphy TJ. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents.Am J Respir Crit Care Med 1998; 157: 351–370.PubMedGoogle Scholar
  13. 13.
    Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, Compton CH. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic.Pulm Pharmacol Ther 1999; 12: 131–135.PubMedCrossRefGoogle Scholar
  14. 14.
    Panettieri RA, Eszterhas A, Cieslinski LB, Torphy TJ. Ariflo® (SB 207499) modulates human airway smooth muscle cell proliferation induced by mitogens.Am J Respir Crit Care Med 2000; 161: A697.Google Scholar
  15. 15.
    Shrewsbury S, Pyke S, Britton M. A meta-analysis of incresing inhaled steroid or adding salmeterol in symptomatic asthma (MIASMA).BMJ 2000; 320: 1368–1373.PubMedCrossRefGoogle Scholar
  16. 16.
    Evans DJ, Taylor DA, Zetterstrom O, Fan Chung K, O’Connor BJ, Barnes PJ. A comparison of low dose inhaled budesonide plus theophylline and high dose inhaled budesonide for moderate asthma.N Engl J Med 1997; 337: 1412–1418.PubMedCrossRefGoogle Scholar
  17. 17.
    Wilson AJ, Gibson PG, Coughlan J. Long-acting beta-agonists versus theophylline for maintenance treatment of asthma.Cochmne Database Syst Rev 2000; 1: 1–11.Google Scholar
  18. 18.
    Lynch KR, O’Neill GP, Liu Q, Im DS, Sawyer N, Metters KM,et al. Characterization of the human cysteinyl leukotriene CysLTI receptor.Nature 1999; 399: 789–793.PubMedCrossRefGoogle Scholar
  19. 19.
    Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway.N EnglJ Med 1999; 340: 197–206.CrossRefGoogle Scholar
  20. 20.
    Gawchik SM, Saccar CL, Noonan M, Raesner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.J Allergy Clin Immunol 1999; 103: 615–621.PubMedCrossRefGoogle Scholar
  21. 21.
    Edell D, Perlander F, Khoshoo V. Comparative efficacy of levalbuterol (LA) and racemic albuterol (RA) in infants with reactive airway disease (RAD) using crying vital capacity (CVC) measurements.Ann Allergy Asthma Immunol, (in press).Google Scholar
  22. 22.
    Nelson HS, Bensch G, Pleskow WW, DiSantostenfano MS, DeGraw S, Reasner DSet al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.J Allergy Clin Immunol 1998; 102: 943–952.PubMedCrossRefGoogle Scholar
  23. 23.
    Truitt TJ, Witko J, Kotter S, Gordon I. Levalbuterol reduces total and breakthrough treatments in hospitalized patients.Am J Respir Crit Care Med 2000; 137: 248S.Google Scholar
  24. 24.
    Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer C-A, O’Byrne PMet al. Exacerbations of asthma: A descriptive study of 425 severe exacerbations.Am J Respir Crit Care Med 1999; 160: 594–599.PubMedGoogle Scholar
  25. 25.
    Nyce J. Respirable oligonucleotides: A new, third drug class targeting respiratory disease.Current Opinions in Allergy Clin Immunol 2002; 2 (6): 533–536.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2004

Authors and Affiliations

  1. 1.Advanced Pediatrics CentrePost Graduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations